Inyx USA strikes UK deal
Inyx USA, subsidiary of Inyx, the international specialty pharmaceutical company, has been selected to manufacture a novel urological product as a topical hydrofluoroalkane (HFA) aerosol spray for an emerging UK-based firm.
Inyx USA, subsidiary of Inyx, the international specialty pharmaceutical company, has been selected to manufacture a novel urological product as a topical hydrofluoroalkane (HFA) aerosol spray for an emerging UK-based firm.
Md and chairman of parent company Inyx Jack Kachkar, said: "We are very pleased that a new, UK-based client has selected Inyx USA for Phase III trial production. This selection reflects our intensifying, coordinated business development efforts from both sides of the Atlantic".
Inyx USA will initially provide process transfer services to enable production of the clinical trial batches at an enhanced HFA facility at its Manati site in Puerto Rico, which was acquired from Sanofi-Aventis last year.